GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
W.L.Gore & Associates
Study ID
NCT06827990
Status
Recruiting

Conditions

  • Aortic Dissection

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GORE® Ascending Stent Graft (ASG device) — DEVICE
    Endovascular aortic repair of the ascending aorta

Study Details

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

Key Dates

Start date
Sep 22, 2025
Status verified
Apr 2026
Primary completion
Sep 1, 2030
Completion
Sep 1, 2031

Study Design

Enrollment
112 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Primary
    A hypothesis driven analysis of the safety and effectiveness of the GORE® Ascending Stent Graft (ASG) device alone in the ascending aorta. Dissection chronicity in the primary arm must be 30 days or less from symptom onset to index endovascular procedure.
  • Experimental: Secondary
    Descriptive analysis of use of the ASG device in patients who are not eligible for treatment in the primary arm. Dissection chronicity up to 90 days from symptom onset until the first study procedure is allowed in the secondary arm.

Primary Outcome Measure

Primary Safety Endpoint [ Time Frame: 30 Days ]

Central Contacts

Locations (16)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Shelley Schultz
205-641-7880
Kyle Eudailey, MD (PRINCIPAL_INVESTIGATOR)
University of Southern CaliforniaLos AngelesCalifornia90033
Arnoldo Gutierres-Abrica
Fernando Fleischman, MD (PRINCIPAL_INVESTIGATOR)
University of FloridaGainesvilleFlorida32608
Jessica Cobb
352-273-7837
Thomas Beaver, MD (PRINCIPAL_INVESTIGATOR)
Emory University School of MedicineAtlantaGeorgia30322
Maialen Odriozola
Bradley Leshnower, MD (PRINCIPAL_INVESTIGATOR)
Northwestern MedicineChicagoIllinois60611
Andrea Silverman
312-921-0042
Christopher Mehta, MD (PRINCIPAL_INVESTIGATOR)
Indiana UniversityIndianapolisIndiana46202
Emily Rettig
Joel Corvera, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Bronwen Rees-Widermann
Arminder Jassar, MD (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48109
China Green
734-936-7731
Himanshu Patel, MD (PRINCIPAL_INVESTIGATOR)
Corewell Health SystemGrand RapidsMichigan49503
Denise Wittenbach
Stephane Leung, MD (PRINCIPAL_INVESTIGATOR)
Washington University School of Medicine - St. LouisSt LouisMissouri63110
Allison Schuck
Puja Kachroo, MD (PRINCIPAL_INVESTIGATOR)
Duke University Medical CenterDurhamNorth Carolina27710
Rachael Abuin
936-697-0740
G. Chad Hughes, MD (PRINCIPAL_INVESTIGATOR)
Cleveland ClinicClevelandOhio44195
Larissa Schaaf, RN
216-445-4437
Brett Duncan, BS
216-445-9048
Patrick Vargo, MD (PRINCIPAL_INVESTIGATOR)
Ohio Health Research InstituteColumbusOhio43214
Theresa Khuat
Jefferson Lyons, MD (PRINCIPAL_INVESTIGATOR)
Hospital of the University of PennsylvaniaPhiladelphiaPennsylvania18104
Tara Manzari
Nimesh Desai, MD (PRINCIPAL_INVESTIGATOR)
The Methodist Hospital HoustonHoustonTexas77030
Riya Singh
713-441-3142
Marvin Atkins, MD (PRINCIPAL_INVESTIGATOR)
Baylor Research InstitutePlanoTexas75093
Niat Tekle
469-814-4853
William Brinkman, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies